NKTR
SHORT CANDIDATEMeanRevComposite
29.50
Technical
76.40
Fundamental
13.80
Rank
—
Price
75.92
Hurst
0.13
As of
Aug 14, 2026
Daily
Nektar Therapeutics
HealthcareBiotechnologyNektar Therapeutics is a biopharmaceutical company developing immunotherapy treatments for autoimmune, inflammatory, and oncological conditions. The company's pipeline includes multiple drug candidates targeting conditions such as ulcerative colitis, vitiligo, multiple sclerosis, fibrotic diseases, and various cancers. It maintains research partnerships with several major pharmaceutical firms including Takeda, AstraZeneca, Roche, Pfizer, and Bristol-Myers Squibb.
Market cap
$1.3B
P/E (trailing)
—
P/E (forward)
-3.77
PEG ratio
0.31
Dividend yield
0.00%
Beta
1.27
52w range
33.40 – 109.00
Return on equity
-35.76%
Profit margin
-287.84%
Revenue growth
-9.30%
Earnings growth
—
Price history
1Y: 38.87 (-40.1%) · range 35.12–100.35
Cycle position
2/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 81 · STRONG SETUP · exit proximity 0
Conviction
42/ 100 · maturity 29%
VScore.1610
Buildup.2831
EMA entry setup.3581
Fundamentals.2114
Volume profile
POC
68.34
Price vs POC
-43.1%
Overhead supply
93%
Runway
+53.4%
Value area 57.43–76.63 · 93% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.077 | Oct 12, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -6.19% | +4.59% | mature |
| 40d | -45.44% | +4.59% | mature |